LDC provides biopharmaceutical companies with access to high-quality pharmaceutical leads and therapeutic antibodies based on the most innovative findings from leading research institutions. All leads come with proof-of-concept in animal models, solid IP protection and comprehensive data packages, enabling a seamless transition into a company portfolio. Industry partners have the option to stay in contact with LDC and academic partners, consulting and collaborating with them whenever needed and appropriate.

Successful de-risking

From the initial project selection and throughout the drug discovery process, LDC applies stringent go/no-go criteria, making sure that resulting leads have an above-average prospect of success.

Portfolio information

80 Total projects started
18 Industry deals (option/licence/co-development/spin-outs/subsidiary companies)
15 Funding needed/commercialization process
25 Projects actively pursued
12 Projects stopped for scientific reasons

Flexible partnership structure

Depending on your needs and strategic focus we build various forms of alliances and deals including:

  • co-development or collaboration agreements
  • licence agreements
  • strategic partnerships
  • incubation and financing of early project ideas at LDC
  • spin-offs

Your benefits

  • Gain access to highly innovative first-in-class therapy approaches
  • Take on viable leads with preclinical proof-of-concept
  • Get involved early
  • Work with a team that speaks your language and understands industry requirements
  • Expand your network to include excellent scientists and their research organizations
  • Filter project ideas, including validation or de-validation